

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Use as many sheets as necessary Sheet 1 of 1		Complete if Known Application Number: 10/620,271 Filing Date: 07/14/2003 First Named Inventor: Mathiesen Group Art Unit: Examiner Name: Attorney Docket Number: 065334-0111	
--	--	--	--

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MB	A1	US 2003/0018006 A1		Tao et al.	01-23-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶

Examiner Signature	<i>Mark Bruch</i>	Date Considered	9-28-04
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: July 18, 2003

(use as many sheets as necessary)

Complete if Known

Application Number	10/345,410
--------------------	------------

Filing Dat	01/16/2003
-------------------	------------

First Name of Inventor	Bjarne BOGEN
------------------------	--------------

Group Art Unit	1645
----------------	------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	065334-0109
------------------------	-------------

Sheet	1	of	7
-------	---	----	---

[illegible][illegible]

**Examiner
Signature**

Date
Considered

9-28-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 18, 2003 (use as many sheets as necessary) 2 of 7		Application Number	10/345,410
		Filing Date	01/16/2003
		First Named Inventor	Bjarne BOGEN
		Group Art Unit	1645
		Examiner Name	Unknown
		Attorney Docket Number	065334-0109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	A9	Aase, et al., "The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity," <i>J. Immunol. Methods</i> 136, 185-191 (1991)	
	A10	Abe, et al., "Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy," <i>Gene Ther</i> 3:988-993 (1996)	
	A11	Acsadi et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," <i>Nature</i> 352, 815 (1991)	
	A12	Arafat, et al., "Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv," <i>Gene Ther</i> 9:256-262 (2002)	
	A13	Biragyn, et al., "B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions," <i>Immunol Rev</i> 170:115-126 (1999)	
	A14	Bogen and Weiss, "Processing and Presentation of Idiotypes to MHC-Restricted T Cells," <i>Int. Rev. Immunol.</i> 10, 337-355 (1993)	
	A15	Bogen, et al., "Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules," <i>Eur. J. Immunol.</i> 16, 1373-1378 (1986)	
	A16	Chang & Prud'Homme, "Intramuscular Administration of Expression Plasmids Encoding Interferon- γ Receptor/IgG1 or IL-4/IgG1 Chimeric Proteins Protects from Autoimmunity," <i>The Journal of Gene Medicine</i> , 1:415-423 (1999)	
	A17	Chang, et al., "A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice," <i>Journal of Virology</i> , 74(9):4244-4252 (2000)	
	A18	Colombat, et al., "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation," <i>Blood</i> 97, 101-106 (2001)	
	A19	Donoghue, et al., "Rostrocaudal gradient of transgene expression in adult skeletal muscle," <i>Proc. Natl. Acad. Sci., USA</i> 88:5847-5851 (1991)	
MB	A20	Eidem, et al., "Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation," <i>Journal of Immunological Methods</i> , 245:119-131 (2000)	

Examiner Signature	<i>Mark Bohl</i>	Date Considered	9-28-04
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/345,410
Date Submitted: July 18, 2003		Filing Date	01/16/2003
(Use as many sheets as necessary)		First Named Inventor	Bjarne BOGEN
Sheet 3 of 7		Group Art Unit	1645
		Examiner Name	Unknown
		Attorney Docket Number	065334-0109

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MB	A21	Feldmann, et al., "Discovery of TNF- α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies," <i>Joint Bone Spine</i> 69:12-18 (2002)	
	A22	Forconi, et al., "Insight into the potential for DNA idiotype fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses," <i>Immunology</i> 107:39-45 (2002)	
	A23	Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Nat'l Acad. Sci. USA</i> , 85:5879-5883 (1988)	
	A24	King, et al., "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma," <i>Nat Med</i> 4:1281-1286 (1998)	
	A25	Kwak LW, "Translational development of active immunotherapy for hematologic malignancies," <i>Int J Hematol</i> 76(Suppl 1):320-321 (2002)	
	A26	Lang, et al., "On immunoglobulin heavy chain gene switching: two 2b genes are rearranged via switch sequences in MP-11 cells but only one is expressed," <i>Nucleic Acids Res.</i> 10:611-630 (1982)	
	A27	Lauritzsen, et al., "Idiotypic-Specific, Major Histocompatibility Complex Restricted T Cells are of both Th1 and Th2 Type," <i>Scand. J. Immunol.</i> 33:647-656 (1991)	
	A28	Lee, et al., "Surfactant-induced sealing of electroporated skeletal muscle membranes <i>in vivo</i> ," <i>Proc. Nat'l Acad. Sci. USA</i> 89:4524-4528 (1992)	
	A29	Leonard, et al., "Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer," <i>Br. J. Surg.</i> 89:262-271 (2002)	
	A30	Lewis, et al., "Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer," <i>J Virol.</i> 76:8769-8775 (2002)	
	A31	Lunde, et al., "Efficient Delivery of T Cell Epitopes to APC by Use of MHC Class II-Specific Tryptophan," <i>J. Immunol.</i> 168, 2154-2162 (2002)	
	A32	Lunde, et al., "Immunoglobulin as a Vehicle for Foreign Antigenic Peptides Immunogenic to T Cells," <i>Molecular Immunology</i> 34:1167-1176 (1997)	
MB	A33	Lunde, et al., "Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells," <i>Nature Biotechnology</i> 17:670-675 (1999)	

Examiner Signature	<i>Mark Brack</i>	Date Considered	9-28-04
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE OCT 16 2003 PATENT & TRADEMARK OFFICE		Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 18, 2003 (use as many sheets as necessary)		Complete if Known	
		Application Number		10/345,410	
		Filing Date		01/16/2003	
		First Named Inventor		Bjarne BOGEN	
		Group Art Unit		1645	
		Examiner Name		Unknown	
		Attorney Docket Number		065334-0109	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
MB	A34	Mathiesen, I, "Electropermeabilization of skeletal muscle enhances gene transfer <i>in vivo</i> ," <i>Gene Therapy</i> 6(4):508-514 (1999)		
	A35	Michaelsen, et al., "Enhancement of Complement Activation and Cytolysis of Human IgG3 by Deletion of Hinge Exons," <i>Scand. J. Immunol.</i> 32:517-528 (1990)		
	A36	Muscat, et al., "Multiple 5'-Flanking Regions of the Human α -Skeletal Actin Gene Synergistically Modulate Muscle-Specific Expression" <i>Mol. Cell. Biol.</i> 7: 4089-4099 (1987)		
	A37	Neuberger, M., "Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells," <i>EMBO J.</i> 2:1373-1378 (1983)		
	A38	Noël, et al., "Skin as a potential organ for ectopic monoclonal antibody production," <i>The Journal of Investigative Dermatology</i> , 118:288-294 (2002a)		
	A39	Noël, et al., "Sustained Systematic Delivery of Monoclonal Antibodies by Genetically Modified Skin Fibroblasts," <i>The Journal of Investigative Dermatology</i> , 115(4):740-745 (2000)		
	A40	Noël, et al., "High <i>in vivo</i> production of a model monoclonal antibody on adenoviral gene transfer," <i>Hum Gene Ther</i> 13:1483-1493 (2002b)		
	A41	Noël, et al., "In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells," <i>Hum Gene Ther</i> 8:1219-1229 (1997)		
	A42	Norderhaug, et al, "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells," <i>J. Immunol. Methods</i> 204:77-87 (1997)		
	A43	Ozato, et al., "Hybridoma Cell Lines Secreting Monoclonal Antibodies to Mouse H-2 and Ia Antigens," <i>J. Immunol.</i> 124:533-540 (1980)		
MB	A44	Pelegrin, et al., "Immunotherapy of a Viral Disease by in Vivo Production of Therapeutic Monoclonal Antibodies," <i>Human Gene Therapy</i> 11:1407-1415 (2000)		


Examiner Signature	<i>Mark Buch</i>	Date Considered	9-28-04
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO		Complete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/345,410
	Date Submitted: July 18, 2003		Filing Date	01/16/2003
	Use as many sheets as necessary)		First Named Inventor	Bjarne BOGEN
			Group Art Unit	1645
			Examiner Name	Unknown
	5 of 7		Attorney Docket Number	065334-0109

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
MB	A45	Piccirillo & Prud'Homme, "Prevention of Experimental Allergic Encephalomyelitis by Intramuscular Gene Transfer with Cytokine-Encoding Plasmid Vectors," <i>Human Gene Therapy</i> <u>10</u> :1915-1922 (1999)		
	A46	Rice, et al., "Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen," <i>J Immunol</i> <u>169</u> :3908-3913 (2002)		
	A47	Rice, et al., "Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines," <i>Vaccine</i> <u>17</u> :3030-3038 (1999)		
	A48	Rinaldi, et al., "Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotype determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells," <i>Cancer Res</i> <u>61</u> :1555-1562 (2001)		
	A49	Rizzuto, et al., "Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation," <i>Proc. Nat'l Acad. Sci. USA</i> <u>96</u> (11):6417-6422 (1999)		
	A50	Rosenberg, et al., "Gene Transfer into Humans - Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction," <i>New Eng. J. Med.</i> <u>323</u> :570-578 (1990)		
	A51	Ruffini, et al., "Recent advances in multiple myeloma immunotherapy," <i>Biomed Pharmacother</i> <u>56</u> :129-132 (2002)		
	A52	Ruffini, et al., "Idiotype vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines," <i>Haematologica</i> <u>87</u> (9):989-1001 (2002)		
MB	A53	Smith & Nordstrom, "Advances in plasmid gene delivery and expression in skeletal muscle," <i>Current Opinion in Molecular Therapeutics</i> <u>2</u> (2):150-154 (2000)		


Examiner Signature		Date Considered	9-28-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO		Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/345,410	
	Date Submitted: July 18, 2003		Filing Date	01/16/2003	
	Use as many sheets as necessary)		First Named Inventor	Bjame BOGEN	
	6	of	7	Group Art Unit	1645
			Examiner Name	Unknown	
		Attorney Docket Number	065334-0109		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
MB	A54	Sternberg, et al., "Identification of Upstream and Intragenic Regulatory Elements That Confer Cell-Type-Restricted and Differentiation-Specific Expression on the Muscle Creatine Kinase Gene," <i>Mol. Cell. Biol.</i> <u>8</u> (7):2896-2909 (1988)		
	A55	Stevenson, et al., "DNA vaccines against cancer: from genes to therapy," <i>Ann Oncol</i> <u>10</u> :1413-1418 (1999)		
	A56	Stevenson, et al., "DNA vaccines against haematological malignancies," <i>Haematologica</i> <u>84</u> (Suppl EHA-4):11-13 (1999)		
	A57	Stevenson, et al., "DNA vaccination against multiple myeloma," <i>Semin Hematol</i> <u>36</u> :38-42 (1999)		
	A58	Stevenson, et al., "Idiotypic DNA vaccines against B-cell lymphoma," <i>Immunol Rev</i> <u>145</u> :211-228 (1995)		
	A59	Stevenson, et al., "New strategies for vaccination and immunomodulation in NHL," <i>Ann Hematol</i> <u>80</u> (Suppl 3):B132-B134 (2001)		
	A60	Syrengelas, et al., "DNA immunization induces protective immunity against B-cell lymphoma," <i>Nat Med</i> <u>2</u> :1038-1041 (1996)		
	A61	Syrengelas, et al., "DNA vaccination against the idotype of a murine B cell lymphoma: mechanism of tumor protection," <i>J Immunol</i> <u>162</u> :4790-4795 (1999)		
	A62	Tao, et al., "Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG constant Region," <i>J. Immunol.</i> <u>143</u> , 2595-2601 (1989)		
	A63	Thirdborough, et al., "Vaccination with DNA encoding a single-chain TCR fusion protein induces antitumor immunity and protects against T-cell lymphoma," <i>Cancer Res</i> <u>62</u> :1757-1760 (2002)		
MB	A64	Timmerman, et al., "Idiotypic-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas," <i>Blood</i> <u>97</u> (5):1370-1377 (2001)		


Examiner Signature		Date Considered	9-28-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO		Complete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/345,410
	Date Submitted: July 18, 2003		Filing Date	01/16/2003
	Use as many sheets as necessary)		First Named Inventor	Bjarne BOGEN
	Sheet 7 of 7	Group Art Unit	1645	
	Examiner Name	Unknown		
		Attorney Docket Number	065334-0109	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MB	A65	Tsuji-Yamada, et al., "Effect of IL-12 encoding plasmid administration on tight-skin mouse," <i>Biochem Biophys Res. Commun.</i> , 280(3):707-712 (2001)	
	A66	Wolff, et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <i>Science</i> 247:1465-1468 (1990)	
	A67	Zhu, et al., "DNA fusion vaccines against B-cell tumors," <i>Trends Mol Med</i> 7:566-572 (2001)	
	A68	Hofmann, "Cells in electric fields," in E. Neumann, A.E. Sowers, & C.A. Jordan (eds.), <i>ELECTROPORATION AND ELECTROFUSION IN CELL BIOLOGY</i> , pages 389-407 (Plenum Publ. Corp. 1989)	
	A69	Kabat, et al., <i>SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST</i> , 4th ed. U.S. Dept. Health and Human Services, Public Health Services, Bethesda, Md. (1987)	
MB	A70	Williams and Barclay, <i>IMMUNOGLOBULIN GENES</i> (page 361), Academic Press, New York (1989)	

Examiner Signature		Date Considered	9-28-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.